Antiviral Activity of Nobiletin against Chikungunya virus in vitro
Antiviral Therapy · 2017-11 · 22 (8) · 689-697
DOI: 10.3851/imp3167 ↗At a glance
Journal article in Antiviral Therapy, published online on 2016-11-01. Written by Shih-Chao Lin and 4 co-authors. Institution: PhD Program in Medical Biotechnology, National Chung Hsing University, Taichung, Taiwan. Cited 26 times so far (Crossref); 35 references.
Abstract (original language)
Background
Chikungunya virus (CHIKV), a highly contagious re-emerging virus, is transmitted by infected mosquitoes. CHIKV is prevalent in tropical countries and is continuing to creep farther north into temperate areas. CHIKV is responsible for induction of chikungunya fever (CF) and severe joint stiffness with the capability of developing into bilateral and systemic arthralgia or even encephalitis. Despite the high morbidity rate, no approved antiviral drug is available. Therefore, an anti-CHIKV therapy is necessary to control this disease. In this study, we screened four flavonoids for anti-CHIKV activities: nobiletin, phlorizin, resveratrol and oxyresveratrol.
Methods
We performed MTT, Viral ToxGlo TM and lactate dehydrogenase (LDH) assays to assess the viability of CHIKV-infected host cells. Plaque assay and immunofluorescent assay were utilized to evaluate the levels of viral production in quantification and qualification, respectively.
Results
We first confirmed that nobiletin can maintain the cellular survival of infected cells without inducing significant toxicity to host cells. Nobiletin suppressed virus-induced cell death and viral production. Also, the antiviral efficacy of nobiletin can last for at least 48 h during infection. More importantly, nobiletin inhibited CHIKV infection during the translation/replication stages and viral entry, making nobiletin a potential clinical antiviral agent in prophylaxis and post-exposure treatment.
Conclusions
In this study, our results provided a strategy to develop anti-chikungunya agents by utilizing natural compounds. Also, we believe that nobiletin can be a potential antiviral agent against CHIKV infection worthy of being further investigated as a remedial candidate in vivo.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- PhD Program in Medical Biotechnology, National Chung Hsing University, Taichung, Taiwan.
- National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA, USA.
- Center for Infectious Diseases, Discovery Biology, SRI International, Harrisonburg, VA, USA.
- Hubei Collaborative Innovation Center for the Characteristic Resources Exploitation of Dabie Mountains, Hubei Key Laboratory of Economic Forest Germplasm Improvement and Resources Comprehensive Utilization, College of L…
- Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan.
- Department of Biotechnology, Asia University, Taichung, Taiwan.
Cite
APA
Lin, S. C., Chen, M. C., Li, S., Lin, C. C., & Wang, T. T. (2017). Antiviral Activity of Nobiletin against Chikungunya virus in vitro. Antiviral Therapy, 22(8), 689-697. https://doi.org/10.3851/imp3167
Vancouver
Lin SC, Chen MC, Li S, Lin CC, Wang TT. Antiviral Activity of Nobiletin against Chikungunya virus in vitro. Antiviral Therapy. 2017;22(8):689-697. doi:10.3851/imp3167
BibTeX
@article{Lin2017,
author = {Lin, Shih-Chao and Chen, Mei-Chun and Li, Shiming and Lin, Chi-Chen and Wang, Tony T},
title = {Antiviral Activity of Nobiletin against Chikungunya virus in vitro},
journal = {Antiviral Therapy},
year = {2017},
volume = {22},
number = {8},
pages = {689--697},
doi = {10.3851/imp3167}
}
EUVIMED